LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 66

Search options

  1. Article: The Best Predictor of the Future-the Metaverse, Mental Health, and Lessons Learned From Current Technologies.

    Benrimoh, David / Chheda, Forum D / Margolese, Howard C

    JMIR mental health

    2022  Volume 9, Issue 10, Page(s) e40410

    Abstract: The metaverse-a virtual world accessed via virtual reality technology-has been heralded as the next key digital experience. It is meant to provide the next evolution of human interaction after social media and telework. However, in the context of the ... ...

    Abstract The metaverse-a virtual world accessed via virtual reality technology-has been heralded as the next key digital experience. It is meant to provide the next evolution of human interaction after social media and telework. However, in the context of the growing awareness of the risks to mental health posed by current social media technologies, there is a great deal of uncertainty as to the potential effects of this new technology on mental health. This uncertainty is compounded by a lack of clarity regarding what form the metaverse will ultimately take and how widespread its application will be. Despite this, given the nascent state of the metaverse, there is an opportunity to plan the research and regulatory approaches needed to understand it and promote its positive effects while protecting vulnerable groups. In this viewpoint, we examine the following three current technologies whose functions comprise a portion of what the metaverse seeks to accomplish: teleworking, virtual reality, and social media. We attempted to understand in what ways the metaverse may have similar benefits and pitfalls to these technologies but also how it may fundamentally differ from them. These differences suggest potential research questions to be addressed in future work. We found that current technologies have enabled tools such as virtual reality-assisted therapy, avatar therapy, and teletherapy, which have had positive effects on mental health care, and that the metaverse may provide meaningful improvements to these tools. However, given its similarities to social media and its expansion upon the social media experience, the metaverse raises some of the same concerns that we have with social media, such as the possible exacerbation of certain mental health problems. These concerns led us to consider questions such as how the users will be protected and what regulatory mechanisms will be put in place to ensure user safety. Although clear answers to these questions are challenging in this early phase of metaverse research, in this viewpoint, we use the context provided by comparator technologies to provide recommendations to maximize the potential benefits and limit the putative harms of the metaverse. We hope that this paper encourages discussions among researchers and policy makers.
    Language English
    Publishing date 2022-10-28
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 2798262-2
    ISSN 2368-7959
    ISSN 2368-7959
    DOI 10.2196/40410
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Exceptionally High Clozapine-Associated Eosinophilia.

    Rehimini, Salma / Goddard, Karin G / Margolese, Howard C

    Journal of clinical psychopharmacology

    2021  Volume 41, Issue 2, Page(s) 216–218

    MeSH term(s) Adult ; Antipsychotic Agents/administration & dosage ; Antipsychotic Agents/adverse effects ; Clozapine/administration & dosage ; Clozapine/adverse effects ; Eosinophilia/chemically induced ; Female ; Humans ; Schizophrenia/drug therapy
    Chemical Substances Antipsychotic Agents ; Clozapine (J60AR2IKIC)
    Language English
    Publishing date 2021-03-05
    Publishing country United States
    Document type Case Reports ; Letter
    ZDB-ID 604631-9
    ISSN 1533-712X ; 0271-0749
    ISSN (online) 1533-712X
    ISSN 0271-0749
    DOI 10.1097/JCP.0000000000001351
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study.

    Margolese, Howard C / Boucher, Matthieu / Therrien, Francois / Clerzius, Guerline

    BMC psychiatry

    2022  Volume 22, Issue 1, Page(s) 773

    Abstract: Background: ReLiAM, Real-Life Assessment of Abilify Maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (AOM) under real-life ... ...

    Abstract Background: ReLiAM, Real-Life Assessment of Abilify Maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (AOM) under real-life conditions. ReLiAM's primary aim was to evaluate the evolution of global functional status in patients treated with AOM for 12 months in Canada.
    Methods: The objective of this post hoc analysis of the ReLiAM study is to investigate the treatment effects of real-life use of AOM over a 1-year period in the subgroup of patients with reported substance use compared with patients without substance use.
    Results: The results of this post hoc analysis demonstrate that treatment with AOM for 12 months in patients with schizophrenia was comparably effective in improving global functioning in subgroups of patients with and without concomitant substance use.
    Conclusions: These results support the use of AOM for the treatment of schizophrenia in patients with or without concomitant substance use.
    Trial registration: ClinicalTrials.gov NCT02131415, first posted on May 6, 2014. Overall trial status: Terminated.
    MeSH term(s) Humans ; Aripiprazole/therapeutic use ; Schizophrenia/complications ; Schizophrenia/drug therapy ; Prospective Studies ; Canada ; Substance-Related Disorders
    Chemical Substances Aripiprazole (82VFR53I78)
    Language English
    Publishing date 2022-12-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 2050438-X
    ISSN 1471-244X ; 1471-244X
    ISSN (online) 1471-244X
    ISSN 1471-244X
    DOI 10.1186/s12888-022-04397-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic.

    Lai, Jonathan K / Margolese, Howard C

    Schizophrenia research

    2018  Volume 204, Page(s) 443–444

    MeSH term(s) Adult ; Antipsychotic Agents/administration & dosage ; Antipsychotic Agents/adverse effects ; Delayed-Action Preparations ; Health Knowledge, Attitudes, Practice ; Humans ; Injections ; Paliperidone Palmitate/administration & dosage ; Paliperidone Palmitate/adverse effects ; Patient Acceptance of Health Care ; Psychotic Disorders/drug therapy ; Qualitative Research ; Schizophrenia/drug therapy
    Chemical Substances Antipsychotic Agents ; Delayed-Action Preparations ; Paliperidone Palmitate (R8P8USM8FR)
    Language English
    Publishing date 2018-09-18
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 639422-x
    ISSN 1573-2509 ; 0920-9964
    ISSN (online) 1573-2509
    ISSN 0920-9964
    DOI 10.1016/j.schres.2018.09.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Generic formulations of psychotropic medications and treatment response.

    Bhat, Venkat / Margolese, Howard C

    Journal of psychiatry & neuroscience : JPN

    2017  Volume 42, Issue 2, Page(s) E3–E4

    MeSH term(s) Adult ; Depressive Disorder, Major/drug therapy ; Drug Substitution ; Drugs, Generic/therapeutic use ; Humans ; Male ; Psychotropic Drugs/therapeutic use ; Recurrence ; Sertraline/therapeutic use ; Treatment Outcome
    Chemical Substances Drugs, Generic ; Psychotropic Drugs ; Sertraline (QUC7NX6WMB)
    Language English
    Publishing date 2017-02-28
    Publishing country Canada
    Document type Case Reports ; Journal Article
    ZDB-ID 1077443-9
    ISSN 1488-2434 ; 1180-4882
    ISSN (online) 1488-2434
    ISSN 1180-4882
    DOI 10.1503/jpn.160004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: An observational study of antipsychotic medication discontinuation in first-episode psychosis: clinical and functional outcomes.

    Malla, Ashok / Iyer, Srividya N / Joober, Ridha / Rangaswamy, Thara / Ramachandran, Padmavati / Schmitz, Norbert / Taksal, Aarati / Mohan, Greeshma / Margolese, Howard C

    Social psychiatry and psychiatric epidemiology

    2022  Volume 57, Issue 7, Page(s) 1329–1340

    Abstract: Purpose: To study the impact of supervised antipsychotic medication discontinuation on clinical and functional outcomes in first-episode psychosis (FEP) in two different cultural environments.: Method: FEP patients(N = 253), treated in two early ... ...

    Abstract Purpose: To study the impact of supervised antipsychotic medication discontinuation on clinical and functional outcomes in first-episode psychosis (FEP) in two different cultural environments.
    Method: FEP patients(N = 253), treated in two early intervention services (Montreal, Canada and Chennai, India) for 2 years, were assessed for medication use, positive and negative symptom remission and social-occupational functioning at regular intervals.
    Results: Between months 4 and 24 of treatment, 107 patients discontinued medication ('Off'group) as compared to 146 who stayed on medication ('On'group). Medication discontinuation was higher in Chennai as compared to Montreal (n = 80, 49.07% vs n = 27, 16.87%; χ
    Conclusion: Certain cultural environments and patient characteristics may facilitate supervised discontinuation of antipsychotic medication following treatment of an FEP without negative consequences.
    MeSH term(s) Antipsychotic Agents/therapeutic use ; Humans ; India ; Psychotic Disorders/therapy ; Remission Induction ; Social Adjustment
    Chemical Substances Antipsychotic Agents
    Language English
    Publishing date 2022-01-18
    Publishing country Germany
    Document type Journal Article ; Observational Study
    ZDB-ID 623071-4
    ISSN 1433-9285 ; 0037-7813 ; 0933-7954
    ISSN (online) 1433-9285
    ISSN 0037-7813 ; 0933-7954
    DOI 10.1007/s00127-022-02230-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Methylphenidate as Treatment for Clozapine-Induced Sedation in Patients with Treatment-Resistant Schizophrenia.

    Sarfati, David / Lai, Jonathan / Margolese, Howard C

    Clinical schizophrenia & related psychoses

    2018  

    Abstract: Background: Treatment-resistant schizophrenia patients frequently need to be managed with clozapine. However, noncompliance is in-part due to complaints of sedation, fatigue, and low energy. There is little literature reporting on the effectiveness and ... ...

    Abstract Background: Treatment-resistant schizophrenia patients frequently need to be managed with clozapine. However, noncompliance is in-part due to complaints of sedation, fatigue, and low energy. There is little literature reporting on the effectiveness and safety of using stimulants to treat clozapine-induced sedation. We report three cases of treatment-resistant schizophrenia where methylphenidate was used to address these common side-effects.
    Methods: To evaluate the effectiveness and safety of psychostimulants in treatment-resistant schizophrenia, we reviewed 3 extensively documented cases of clozapine-induced sedation treated with methylphenidate for over 2 years, in addition to reviewing the literature on this topic.
    Results: All 3 patients reported improvements in energy and fatigue, along with decreased sedation, while treated with methylphenidate for 27, 30, and 32 months respectively. Clozapine doses ranged between 325mg and 500mg daily; methylphenidate doses ranged between 2.5mg of the immediate-release and 72mg daily of the extended-release formulation. There was no reported or observed increase in psychotic symptoms resulting from treatment with methylphenidate.
    Conclusion: Methylphenidate may be safe and effective in the management of clozapine-induced sedation in treatment-resistant schizophrenia. Large scale, placebo-controlled, double-blind trials are needed to further validate the safety and efficacy of methylphenidate as treatment for clozapine-induced sedation.
    Language English
    Publishing date 2018-06-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2489256-7
    ISSN 1941-2010 ; 1935-1232
    ISSN (online) 1941-2010
    ISSN 1935-1232
    DOI 10.3371/CSRP.SALA.061518
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Switching medication products during the treatment of psychiatric illness.

    Blier, Pierre / Margolese, Howard C / Wilson, E Adriana / Boucher, Matthieu

    International journal of psychiatry in clinical practice

    2019  Volume 23, Issue 1, Page(s) 2–13

    Abstract: Background: The common practice of switching between branded (reference) medications and their corresponding generic products, between generic products, or even from a generic product to a branded medication during the treatment of central nervous ... ...

    Abstract Background: The common practice of switching between branded (reference) medications and their corresponding generic products, between generic products, or even from a generic product to a branded medication during the treatment of central nervous system (CNS) disorders may compromise efficacy and/or tolerability.
    Methods: We assessed the published literature from March 1, 2010 through June 30, 2017 via PubMed using the MeSH term 'generics, drugs' alone and in combination with class-specific terms (e.g., 'anticonvulsants', 'mood stabilisers'), for studies detailing outcomes following product switches.
    Results: Although some studies comparing the initiation of reference versus generic drugs suggest equivalence between products, several studies detailing a switch between reference and generic products describe reductions in efficacy, reduced medication adherence and persistence, and increased overall health care resource utilization and costs associated with generic substitution.
    Conclusion: When product switches are considered, they should only proceed with the full knowledge of both patient and provider.
    MeSH term(s) Drug Substitution/adverse effects ; Humans ; Mental Disorders/drug therapy ; Psychotropic Drugs/pharmacokinetics
    Chemical Substances Psychotropic Drugs
    Language English
    Publishing date 2019-02-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1465531-7
    ISSN 1471-1788 ; 1365-1501
    ISSN (online) 1471-1788
    ISSN 1365-1501
    DOI 10.1080/13651501.2018.1508724
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Trust of patients and families in mental healthcare providers and institutions: A cross-cultural study in Chennai, India and Montreal, Canada.

    Xavier, Salome M / Malla, Ashok / Mohan, Greeshma / Mustafa, Sally / Padmavati, Ramachandran / Rangaswamy, Thara / Joober, Ridha / Schmitz, Norbert / Margolese, Howard C / Iyer, Srividya N

    Research square

    2023  

    Abstract: Purpose: Cross-cultural psychosis research has typically focused on a limited number of outcomes (generally symptom-related). It is unknown if the purported superior outcomes for psychosis in some low- and middle-income countries extend to fundamental ... ...

    Abstract Purpose: Cross-cultural psychosis research has typically focused on a limited number of outcomes (generally symptom-related). It is unknown if the purported superior outcomes for psychosis in some low- and middle-income countries extend to fundamental treatment processes like trust. Addressing this gap, we studied two similar first-episode psychosis programs in Montreal, Canada and Chennai, India. We hypothesized higher trust in healthcare institutions and providers among patients and families in Chennai at baseline and over follow-up.
    Methods: Upon treatment entry and at months 3, 12 and 24, trust in healthcare providers was measured using the Wake Forest Trust scale and trust in the healthcare and mental healthcare systems using two single items. Non-parametric tests were performed to compare trust levels across sites and mixed-effects linear regression models to investigate predictors of trust in healthcare providers.
    Results: The study included 333 patients (Montreal=165, Chennai=168) and 324 family members (Montreal=128, Chennai=168). Across all timepoints, Chennai patients and families had higher trust in healthcare providers and the healthcare and mental healthcare systems. The effect of site on trust in healthcare providers was significant after controlling for sociodemographic characteristics known to impact trust. Patients' trust in doctors increased over follow-up.
    Conclusion: This study uniquely focuses on trust as an outcome in psychosis, via a comparative longitudinal analysis of different trust dimensions and predictors, across two geographical settings. The consistent differences in trust levels between sites may be attributable to local cultural values and institutional structures and processes and underpin cross-cultural variations in treatment engagement and outcomes.
    Language English
    Publishing date 2023-02-17
    Publishing country United States
    Document type Preprint
    DOI 10.21203/rs.3.rs-2584056/v1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Trust of patients and families in mental healthcare providers and institutions: a cross-cultural study in Chennai, India, and Montreal, Canada.

    Xavier, Salomé M / Malla, Ashok / Mohan, Greeshma / Mustafa, Sally / Padmavati, Ramachandran / Rangaswamy, Thara / Joober, Ridha / Schmitz, Norbert / Margolese, Howard C / Iyer, Srividya N

    Social psychiatry and psychiatric epidemiology

    2023  

    Abstract: Purpose: Cross-cultural psychosis research has typically focused on a limited number of outcomes (generally symptom-related). It is unknown if the purported superior outcomes for psychosis in some low- and middle-income countries extend to fundamental ... ...

    Abstract Purpose: Cross-cultural psychosis research has typically focused on a limited number of outcomes (generally symptom-related). It is unknown if the purported superior outcomes for psychosis in some low- and middle-income countries extend to fundamental treatment processes like trust. Addressing this gap, we studied two similar first-episode psychosis programs in Montreal, Canada, and Chennai, India. We hypothesized higher trust in healthcare institutions and providers among patients and families in Chennai at baseline and over follow-up.
    Methods: Upon treatment entry and at months 3, 12 and 24, trust in healthcare providers was measured using the Wake Forest Trust scale and trust in the healthcare and mental healthcare systems using two single items. Nonparametric tests were performed to compare trust levels across sites and mixed-effects linear regression models to investigate predictors of trust in healthcare providers.
    Results: The study included 333 patients (Montreal = 165, Chennai = 168) and 324 family members (Montreal = 128, Chennai = 168). Across all timepoints, Chennai patients and families had higher trust in healthcare providers and the healthcare and mental healthcare systems. The effect of site on trust in healthcare providers was significant after controlling for sociodemographic characteristics known to impact trust. Patients' trust in doctors increased over follow-up.
    Conclusion: This study uniquely focuses on trust as an outcome in psychosis, via a comparative longitudinal analysis of different trust dimensions and predictors, across two geographical settings. The consistent differences in trust levels between sites may be attributable to local cultural values and institutional structures and processes and underpin cross-cultural variations in treatment engagement and outcomes.
    Language English
    Publishing date 2023-10-18
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 623071-4
    ISSN 1433-9285 ; 0037-7813 ; 0933-7954
    ISSN (online) 1433-9285
    ISSN 0037-7813 ; 0933-7954
    DOI 10.1007/s00127-023-02576-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top